Autonomix Medical, Inc.

What they do

Autonomix is developing a platform that combines high-sensitivity neural signal detection with targeted radiofrequency ablation, which the company describes as a "sense, treat, verify" approach. The company is pre-commercial and is focused on advancing technologies for sensing and treating disorders of the nervous system. It is based in The Woodlands, Texas, and its common stock trades on the Nasdaq Stock Market under the symbol AMIX. No products are commercially released and no revenue has been recorded.

Revenue drivers

• No commercial product revenue — Reported revenue was $0.00 in each of 2023, 2024, 2025 and 2026, and $0.00 in each of the last four reported quarters through 2026-06-30.
• Sense, treat, verify platform — The development-stage platform integrates neural signal detection with targeted radiofrequency ablation; no product sales or pricing have been reported.
• Clinical-stage pipeline — Value is tied to clinical trial progress rather than sales; filings reference ongoing and future clinical trials as a stated forward-looking item.

Recent performance

The company has generated no revenue in any reported period; annual revenue was $0.00 in 2023, 2024, 2025 and 2026, and quarterly revenue was $0.00 for the quarters ended 2025-09-30, 2025-12-31, 2026-03-31 and 2026-06-30. Net losses were $2.0M in 2023, $15.4M in 2024, $11.4M in 2025 and $16.7M in 2026. Operating cash flow was negative $1.9M in 2023, negative $6.6M in 2024, negative $8.3M in 2025 and negative $12.3M in 2026. As of 2026-06-30, total assets were $4.0M, total liabilities $818,000, shareholder equity $3.2M and cash and equivalents $3.5M. Diluted EPS was negative $0.17 in 2023, negative $14.82 in 2024, negative $6.46 in 2025 and negative $2.32 in 2026.

Strategy

Management describes the company as a development-stage medical device company focused on advancing technologies for sensing and treating disorders of the nervous system. The stated direction centers on the "sense, treat, verify" platform, which pairs neural signal detection with targeted radiofrequency ablation. Forward-looking items in the filings include the success of ongoing and future clinical trials, establishing or maintaining collaborations and licensing arrangements, and obtaining components from third-party manufacturers. The company also cites raising additional capital to support future growth and liquidity and going concern among its stated considerations.

Risks

• No revenue and recurring losses — Revenue has been $0.00 in every reported period while net losses were $16.7M in fiscal 2026.
• Liquidity and going concern — The company lists liquidity and going concern, and the need to raise additional capital, among its stated forward-looking considerations; cash was $3.5M at 2026-06-30.
• Clinical trial dependence — Value depends on the success of ongoing and future clinical trials, which the company identifies as a forward-looking item.
• Nasdaq listing — An 8-K filed 2026-01-16 reported a delisting notice or listing-rule failure, and the filings cite maintaining the Nasdaq Capital Market listing as a consideration.

Outlook

The filings do not report revenue guidance or commercial timelines; forward-looking items center on clinical trials, collaborations and licensing, and capital raising. Management flags liquidity and going concern and the ability to raise additional capital to support future growth. The company also notes risks around third-party manufacturers and obtaining all parts required to manufacture its devices. Diligence would focus on trial progress and financing, since no revenue has been recorded.